Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors Journal Article
| Authors: | Vuky, J.; McCaffrey, J.; Ginsberg, M.; Mariani, T.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J. |
| Article Title: | Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors |
| Abstract: | Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumours. |
| Keywords: | adult; clinical article; middle aged; human cell; clinical trial; neutropenia; cisplatin; drug efficacy; antineoplastic agents; neurotoxicity; carboplatin; phase 2 clinical trial; anemia; leukopenia; nausea; thrombocytopenia; lorazepam; hemoglobin; pyrazoles; testicular neoplasms; thrombocyte count; leukocyte count; germ cell tumor; mediastinal neoplasms; granulocyte colony stimulating factor; acridines; germinoma; hemoglobin determination; 2 (2 dimethylaminoethyl) 9 methoxy 5 nitropyrazolo[3,4,5 kl]acridine; pyrazinamide; humans; human; male; female; priority journal; article; cisplatin-refractory; pyrazoloacridine |
| Journal Title: | Investigational New Drugs |
| Volume: | 18 |
| Issue: | 3 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 2000-08-01 |
| Start Page: | 265 |
| End Page: | 267 |
| Language: | English |
| DOI: | 10.1023/a:1006434008357 |
| PUBMED: | 10958596 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 18 November 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work